Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.

Category Primary study
JournalScandinavian journal of infectious diseases
Year 2008
Alemtuzumab is an antibody binding to CD52, an antigen expressed on lymphocytes. This immunotherapy has been tested as potential therapy in haematological malignancies. We report adenoviral and enteroviral infections and an EBV positive B-cell lymphoma after alemtuzumab therapy. These fatal opportunistic complications have been rarely, if ever, reported before.
Epistemonikos ID: 9c4f0ea4808fc9dd6106dd9ac85f1487175c80df
First added on: Jul 06, 2022